BeOne Medicines AG
ONC · Price history
Price at last available close
$366.06
−$0.94 (-0.26%) 1M
2026-10-27
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About BeOne Medicines AG
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC.
How they make money
BeOne Medicines is a global oncology company that discovers, develops, and commercializes innovative cancer treatments. It generates revenue primarily through the sale of its proprietary pharmaceutical products and through strategic collaborations and licensing agreements with other pharmaceutical companies.
Products & services
The company develops and markets oncology therapies including BRUKINSA (zanubrutinib), TEVIMBRA (tislelizumab), and a pipeline of solid tumor and hematology assets.
Brands & revenue mix
A foundational medicine for the treatment of various hematological malignancies.
Separate brand revenue is not available in this research.Source
A key asset in the company's solid tumor pipeline.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer concentration
The company does not disclose specific customer concentration percentages in its 2025 annual report.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company utilizes various third-party contract manufacturers for the production of its pharmaceutical products; specific supplier names are not disclosed.Source
Business relationships & partnerships
- Novartis Pharma AG — A market development agreement under which Novartis has rights to promote and market certain products in China.Source
Competitors
Strengths
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
66
Fair
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
67
Fair
Financial Strength
54
Business Quality / Moat
66
Management
100
Growth Quality
72
Risk / Durability
32
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
80
Fair
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
78/100
Building Historical Record
Model Score 78/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is mixed across its combined quality, valuation and risk inputs. Review the category scores to identify what is helping or hurting the result.
At today’s price, the WSS valuation framework currently reads as relatively attractive.
The model outlook is currently positive.
- •Valuation scores attractively
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for ONC
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can ONC maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is ONC's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is ONC likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •Is ONC's valuation discount tied to a temporary concern or to a longer-term business risk?
Essential Investment Snapshot
Wall Street Score
66
Opportunity Score
80
Market Cap
$39.12B
P/E Ratio
4.6
EPS
$76.05
52-Week High
$385.22
52-Week Low
$253.95
Beta
0.52
Intrinsic Value
$2927.92
Analyst Target
$400.00
Shares Outstanding
113.4M
Total Revenue
$6.13B
Total Debt
$1.14B
Dividend
No current dividend
Liquidation Value / Share
$45.61
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on ONC.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Global commercial organization.
- +Strong financial position with significant cash reserves.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on clinical trial success and regulatory approvals.
- −Intense competition in the oncology pharmaceutical industry.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
3 historical score records availablePrevious Score
66
Oct 1, 2026
Change
+0.1
points
Current Score
66
Oct 12, 2026
Category Changes
ONC increased 0.1 points because overall fundamentals improved.
Projected Score
Projected Score
74
Projected Change
+8.2 points
Preliminary comparable-period financial changes suggest improvement of approximately 8.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Review model assumptionsThis model estimate is more than three times the share price.
This is a formula-based estimate, not a verified fair value or price target. Check the earnings and growth assumptions.
Stored EPS: $76.05 · Growth assumption: 15.0% · Earnings multiplier: 38.5×.
Current Price
$366.06
Model Intrinsic Value
$2927.92
Difference
−$2561.87
-87.5% vs IV
Margin of Safety
87.5%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.13B | $5.34B | $3.81B | $2.46B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $680.7M | $668.5M | $594.1M | $379.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $5.45B | $4.67B | $3.22B | $2.08B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $2.29B | $2.15B | $1.95B | $1.78B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $2.23B | $2.08B | $1.83B | $1.51B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $4.53B | $4.23B | $3.78B | $3.29B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $1.16B | $616.8M | -$361.2M | -$738.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $923.1M | $447.1M | -$568.2M | -$1.21B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $72.6M | $58.2M | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $868.1M | $416.9M | -$533.0M | -$825.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $212.4M | $129.9M | $111.8M | $55.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $655.7M | $286.9M | -$644.8M | -$881.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $76.05 | $33.80 | $-6.12 | $-8.45 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 112M | 109M | 105M | 104M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 116M | 113M | 105M | 104M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$1.71B
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$26.65
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+11.5%
Cash Change
+85.0%
Margin Change
+6.7 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels, net income margin. Pressure indicators included debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 29.6%. EPS increased 3072.6%. Cash increased 85.0%. Total debt increased 11.5%. Net income margin improved by 6.7 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
49
Smart Money
49
Number of Gurus
2
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
BeOne Medicines (NASDAQ:ONC) Insider Sells $10,890,166.73 in Stock
Comparing Aurora Cannabis (NASDAQ:ACB) & BeOne Medicines (NASDAQ:ONC)
Rumor Mill · ONC
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial